07/07/2017 - 12:00 - Sala Xipre, 173.06

Dual role of the p62/mTORC1 complex in cancer

Scientific sessions, PRBB CRG Conferences

Maria T. Diaz-Meco

Cancer Metabolism and Signaling Networks Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute. La Jolla, USA

Maria Diaz-Meco, from the Sanford Burnham Prebys Medical Discovery Institute in California, US, focuses on defining novel signaling molecules as potential therapeutic targets for the treatment of prostate cancer (PCa). There are two main areas of research in her laboratory: The first one is focused on the study of the cooperation of tumor suppressors in PCa to define how these molecular networks operate to modulate carcinogenesis and tumor aggressiveness. The other one is aimed at understanding how obesity-driven inflammation impacts PCa progression. She has been invited by Pura Muñoz-Cànoves (UPF).